West Pharmaceutical CEO buys more shares; Saudi Arabian pharma manufacturing to grow; NeuroVive does deal for South Korea;

> West Pharmaceutical Services ($WST) CEO Mark Green bought 18,300 shares of the company's stock at an average price of $54.89 per share last week in an open market transaction last week, giving him direct ownership of 18,300 shares. Article

> Spimaco's CEO, Fahad bin Ibrahim Al Khalaf, sees even greater growth of pharmaceutical manufacturing in Saudi Arabia in the coming years. Article

> NeuroVive Pharmaceutical said its Asia group has signed a deal with Sanofi's ($SNY) local affiliate to develop and market CicloMulsion in South Korea. Release

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.